INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
INmune Bio Inc. - Common stock (INMB)
Company Research
Source: GlobeNewswire
Boca Raton, Florida, Sept. 03, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that management will participate in the following investor conferences in September and October, 2024. Baird 2024 Global Healthcare Conference New York, NY; September 10-11, 2024Presentation Time: Tuesday, September 10 at 8:30-9:00 AM Eastern TimeLocation: Session III, Empire Ballroom B, Mezzanine Level About INmune Bio Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively ne
Show less
Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INMB alerts
High impacting INmune Bio Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
INMB
News
- INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Raymond James. They set an "outperform" rating and a $18.00 price target on the stock.MarketBeat
- INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing CohortGlobeNewswire
- INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB EndpointsGlobeNewswire
- INmune Bio Announces $13.0 Million Registered Direct OfferingGlobeNewswire
- INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions [Yahoo! Finance]Yahoo! Finance
INMB
Sec Filings
- 9/26/24 - Form 8-K
- 9/17/24 - Form 8-K
- 9/16/24 - Form 4
- INMB's page on the SEC website